Dasatinib and Severe Pulmonary Hypertension
Author Information
Author(s): Hennigs Jan K, Keller Gunhild, Baumann Hans Jörg, Honecker Friedemann, Kluge Stefan, Bokemeyer Carsten, Brümmendorf Tim H, Klose Hans
Primary Institution: University Medical Centre Hamburg - Eppendorf
Hypothesis
Does dasatinib itself trigger pre-capillary pulmonary hypertension?
Conclusion
Dasatinib may trigger drug-associated pre-capillary pulmonary hypertension, and systematic screening of patients on this medication is recommended.
Supporting Evidence
- The patient developed severe pre-capillary pulmonary hypertension after 32 months of dasatinib therapy.
- Echocardiography showed a right ventricular systolic pressure of 73 mm Hg.
- After stopping dasatinib and starting sildenafil, the patient's symptoms improved significantly.
Takeaway
A patient developed serious lung problems after taking a cancer drug called dasatinib for a long time, suggesting the drug might cause these issues.
Methodology
Case report of a patient with chronic myeloid leukemia who developed pulmonary hypertension while on dasatinib therapy.
Limitations
The true incidence of dasatinib-associated pulmonary hypertension is unclear due to a lack of systematic data.
Participant Demographics
One 70-year-old male patient with chronic phase CML.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website